Grant Number:	1R01CA192393-01 Interpret this number
Primary Investigator:	Couch, Fergus
Organization:	Mayo Clinic Rochester
Project Title:	Risk and Penetrance of Mutations From Breast Cancer Testing Panels.
Fiscal Year:	2014

DESCRIPTION (provided by applicant): Breast cancer is one of the most common cancers in the US. Approximately 15% to 20% of cases exhibit a family history of the disease suggesting a strong heritable component. Susceptibility to breast cancer is associated with high-penetrance germline mutations in BRCA1, BRCA2, PTEN, STK11, CDH1, and TP53. In addition, inherited inactivating mutations in several other genes have been associated with familial breast cancer. These include ATM, CHEK2, PALB2, BRIP1, BARD1, RAD51C, RAD51D, XRCC2, NBN, RAD50, and MRE11A. While inactivating mutations in ATM and CHEK2 have been associated with moderate 3 to 7-fold increased risk of breast cancer with lifetime risks of between 20% and 50%, these risk estimates are imprecise and little is known about the risk of breast and other cancers associated with inactivating mutations in the other predisposition genes. Clinical genetic testing for all of these high and moderate risk predisposition genes is now available. Many women, with personal and family history of breast, ovarian or other cancers, are pursuing testing for mutations with these panels, which has seen an upsurge in demand in response to 'Angelina's story'. Initial data suggest that ~10% of panel tests identify truncating mutations and 20% yield variants of uncertain significance (VUS) in the form of missense and intronic changes of undefined clinical relevance in the known predisposition genes. Although potentially useful for establishing the etiology of breast cancer in a patient's family, there remain significant limitatins in the clinical interpretation of the results from the panel testing. In particular, the age-relate risk of breast and other cancers associated with mutations in the genes are largely undefined. Furthermore, clear medical management recommendations for mutation carriers have not been developed. Thus, the results of these tests can lead to confusion and uninformed medical decisions that can result in significant harm. We propose to use high-throughput mutation screening of known breast cancer predisposition genes in breast cancer case-control studies and high-risk breast cancer families to establish the risks of breast and other cancers associated with deleterious mutations in these genes as follows: Aim 1) Establish the risk of breast cancer in the general population associated with mutations in known predisposition genes using large cohort-based case-control studies; Aim 2) Define the penetrance of cancers associated with inactivating mutations in panel-based predisposition genes through breast cancer family studies; Aim 3) Determine the clinical relevance of VUS in the known predisposition genes. At the conclusion of the study, we expect to establish risk estimates associated with deleterious mutations in the genes for the general population and breast cancer families, leading to much improved risk assessment for mutation carriers. In addition, we expect to establish the clinical relevance of many VUS in the known predisposition genes. The results of this study will also provide the necessary data to establish standard of care medical management recommendations for carriers of deleterious mutations in moderate penetrance genes, a critical unmet need.




Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk.
Authors: Barnes D.R. , Tyrer J.P. , Dennis J. , Leslie G. , Bolla M.K. , Lush M. , Aeilts A.M. , Aittomäki K. , Andrieu N. , Andrulis I.L. , et al. .
Source: Medrxiv : The Preprint Server For Health Sciences, 2024-03-04 00:00:00.0; , .
EPub date: 2024-03-04 00:00:00.0.
PMID: 38496424
Related Citations

Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel.
Authors: Levi H. , Carmi S. , Rosset S. , Yerushalmi R. , Zick A. , Yablonski-Peretz T. , BCAC Consortium , Wang Q. , Bolla M.K. , Dennis J. , et al. .
Source: Journal Of Medical Genetics, 2023-11-27 00:00:00.0; 60(12), p. 1186-1197.
EPub date: 2023-11-27 00:00:00.0.
PMID: 37451831
Related Citations

ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk.
Authors: Stolarova L. , Kleiblova P. , Zemankova P. , Stastna B. , Janatova M. , Soukupova J. , Achatz M.I. , Ambrosone C. , Apostolou P. , Arun B.K. , et al. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2023-08-15 00:00:00.0; 29(16), p. 3037-3050.
PMID: 37449874
Related Citations

A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry.
Authors: Middha P. , Wang X. , Behrens S. , Bolla M.K. , Wang Q. , Dennis J. , Michailidou K. , Ahearn T.U. , Andrulis I.L. , Anton-Culver H. , et al. .
Source: Breast Cancer Research : Bcr, 2023-08-09 00:00:00.0; 25(1), p. 93.
EPub date: 2023-08-09 00:00:00.0.
PMID: 37559094
Related Citations

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.
Authors: Morra A. , Schreurs M.A.C. , Andrulis I.L. , Anton-Culver H. , Augustinsson A. , Beckmann M.W. , Behrens S. , Bojesen S.E. , Bolla M.K. , Brauch H. , et al. .
Source: Cancer Medicine, 2023-07-03 00:00:00.0; , .
EPub date: 2023-07-03 00:00:00.0.
PMID: 37401034
Related Citations

Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival.
Authors: Lopes Cardozo J.M.N. , Andrulis I.L. , Bojesen S.E. , Dörk T. , Eccles D.M. , Fasching P.A. , Hooning M.J. , Keeman R. , Nevanlinna H. , Rutgers E.J.T. , et al. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2023-04-01 00:00:00.0; 41(10), p. 1849-1863.
EPub date: 2023-01-23 00:00:00.0.
PMID: 36689693
Related Citations

Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2.
Authors: Yadav S. , Boddicker N.J. , Na J. , Polley E.C. , Hu C. , Hart S.N. , Gnanaolivu R.D. , Larson N. , Holtegaard S. , Huang H. , et al. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2023-03-20 00:00:00.0; 41(9), p. 1703-1713.
EPub date: 2023-01-09 00:00:00.0.
PMID: 36623243
Related Citations

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.
Authors: Morra A. , Schreurs M.A.C. , Andrulis I.L. , Anton-Culver H. , Augustinsson A. , Beckmann M.W. , Behrens S. , Bojesen S.E. , Bolla M.K. , Brauch H. , et al. .
Source: Research Square, 2023-02-13 00:00:00.0; , .
EPub date: 2023-02-13 00:00:00.0.
PMID: 36824750
Related Citations

Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry.
Authors: Mueller S.H. , Lai A.G. , Valkovskaya M. , Michailidou K. , Bolla M.K. , Wang Q. , Dennis J. , Lush M. , Abu-Ful Z. , Ahearn T.U. , et al. .
Source: Genome Medicine, 2023-01-26 00:00:00.0; 15(1), p. 7.
EPub date: 2023-01-26 00:00:00.0.
PMID: 36703164
Related Citations

A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: application to BRCA1 and BRCA2.
Authors: Zanti M. , O'Mahony D.G. , Parsons M.T. , Li H. , Dennis J. , Aittomäkkiki K. , Andrulis I.L. , Anton-Culver H. , Aronson K.J. , Augustinsson A. , et al. .
Source: Human Mutation, 2023; 2023, .
EPub date: 2023-09-14 00:00:00.0.
PMID: 38725546
Related Citations

Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.
Authors: Li H. , Engel C. , Hoya M. , Peterlongo P. , Yannoukakos D. , Livraghi L. , Radice P. , Thomassen M. , Hansen T.V.O. , Gerdes A.M. , et al. .
Source: Genetics In Medicine : Official Journal Of The American College Of Medical Genetics, 2022 Oct; 24(10), p. 2208.
PMID: 36205748
Related Citations

Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study.
Authors: Dixon-Suen S.C. , Lewis S.J. , Martin R.M. , English D.R. , Boyle T. , Giles G.G. , Michailidou K. , Bolla M.K. , Wang Q. , Dennis J. , et al. .
Source: British Journal Of Sports Medicine, 2022 Oct; 56(20), p. 1157-1170.
EPub date: 2022-09-06 00:00:00.0.
PMID: 36328784
Related Citations

Fanconi anemia caused by biallelic inactivation of BRCA2 can present with an atypical cancer phenotype in adulthood.
Authors: Maxwell K.N. , Patel V. , Nead K.T. , Merrill S. , Clark D. , Jiang Q. , Wubbenhorst B. , D'Andrea K. , Cohen R.B. , Domchek S.M. , et al. .
Source: Clinical Genetics, 2022-09-12 00:00:00.0; , .
EPub date: 2022-09-12 00:00:00.0.
PMID: 36089892
Related Citations

Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study.
Authors: Chen F. , Park S.L. , Wilkens L.R. , Wan P. , Hart S.N. , Hu C. , Yadav S.S. , Couch F.J. , Conti D.V. , de Smith A.J. , et al. .
Source: Cancer Research, 2022-07-14 00:00:00.0; , .
EPub date: 2022-07-14 00:00:00.0.
PMID: 35834270
Related Citations

An integrative model for the comprehensive classification of BRCA1 and BRCA2 variants of uncertain clinical significance.
Authors: Iversen E.S. , Lipton G. , Hart S.N. , Lee K.Y. , Hu C. , Polley E.C. , Pesaran T. , Yussuf A. , LaDuca H. , Chao E. , et al. .
Source: Npj Genomic Medicine, 2022-06-03 00:00:00.0; 7(1), p. 35.
EPub date: 2022-06-03 00:00:00.0.
PMID: 35665744
Related Citations

Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response.
Authors: Thompson K.J. , Leon-Ferre R.A. , Sinnwell J.P. , Zahrieh D.M. , Suman V.J. , Metzger F.O. , Asad S. , Stover D.G. , Carey L. , Sikov W.M. , et al. .
Source: Nar Cancer, 2022 Jun; 4(2), p. zcac018.
EPub date: 2022-06-17 00:00:00.0.
PMID: 35734391
Related Citations

Rare germline copy number variants (CNVs) and breast cancer risk.
Authors: Dennis J. , Tyrer J.P. , Walker L.C. , Michailidou K. , Dorling L. , Bolla M.K. , Wang Q. , Ahearn T.U. , Andrulis I.L. , Anton-Culver H. , et al. .
Source: Communications Biology, 2022-01-18 00:00:00.0; 5(1), p. 65.
EPub date: 2022-01-18 00:00:00.0.
PMID: 35042965
Related Citations

Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.
Authors: Yadav S. , Hu C. , Nathanson K.L. , Weitzel J.N. , Goldgar D.E. , Kraft P. , Gnanaolivu R.D. , Na J. , Huang H. , Boddicker N.J. , et al. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2021-12-10 00:00:00.0; 39(35), p. 3918-3926.
EPub date: 2021-10-21 00:00:00.0.
PMID: 34672684
Related Citations

Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
Authors: Boddicker N.J. , Hu C. , Weitzel J.N. , Kraft P. , Nathanson K.L. , Goldgar D.E. , Na J. , Huang H. , Gnanaolivu R.D. , Larson N. , et al. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2021-11-01 00:00:00.0; 39(31), p. 3430-3440.
EPub date: 2021-07-22 00:00:00.0.
PMID: 34292776
Related Citations

Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis.
Authors: Escala-Garcia M. , Canisius S. , Keeman R. , Beesley J. , Anton-Culver H. , Arndt V. , Augustinsson A. , Becher H. , Beckmann M.W. , Behrens S. , et al. .
Source: Scientific Reports, 2021-10-05 00:00:00.0; 11(1), p. 19787.
EPub date: 2021-10-05 00:00:00.0.
PMID: 34611289
Related Citations

The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.
Authors: Lakeman I.M.M. , van den Broek A.J. , Vos J.A.M. , Barnes D.R. , Adlard J. , Andrulis I.L. , Arason A. , Arnold N. , Arun B.K. , Balmaña J. , et al. .
Source: Genetics In Medicine : Official Journal Of The American College Of Medical Genetics, 2021 Sep; 23(9), p. 1726-1737.
EPub date: 2021-06-10 00:00:00.0.
PMID: 34113011
Related Citations

Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States.
Authors: Domchek S.M. , Yao S. , Chen F. , Hu C. , Hart S.N. , Goldgar D.E. , Nathanson K.L. , Ambrosone C.B. , Haiman C.A. , Couch F.J. , et al. .
Source: Jama Oncology, 2021-07-01 00:00:00.0; 7(7), p. 1045-1050.
PMID: 34042955
Related Citations

Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score.
Authors: Gao C. , Polley E.C. , Hart S.N. , Huang H. , Hu C. , Gnanaolivu R. , Lilyquist J. , Boddicker N.J. , Na J. , Ambrosone C.B. , et al. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2021-06-08 00:00:00.0; , p. JCO2001992.
EPub date: 2021-06-08 00:00:00.0.
PMID: 34101481
Related Citations

Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.
Authors: Fasching P.A. , Yadav S. , Hu C. , Wunderle M. , Häberle L. , Hart S.N. , Rübner M. , Polley E.C. , Lee K.Y. , Gnanaolivu R.D. , et al. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2021-05-20 00:00:00.0; 39(15), p. 1619-1630.
EPub date: 2021-03-29 00:00:00.0.
PMID: 33780288
Related Citations

Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance.
Authors: Richardson M.E. , Hu C. , Lee K.Y. , LaDuca H. , Fulk K. , Durda K.M. , Deckman A.M. , Goldgar D.E. , Monteiro A.N.A. , Gnanaolivu R. , et al. .
Source: American Journal Of Human Genetics, 2021-03-04 00:00:00.0; 108(3), p. 458-468.
EPub date: 2021-02-19 00:00:00.0.
PMID: 33609447
Related Citations

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.
Authors: Coignard J. , Lush M. , Beesley J. , O'Mara T.A. , Dennis J. , Tyrer J.P. , Barnes D.R. , McGuffog L. , Leslie G. , Bolla M.K. , et al. .
Source: Nature Communications, 2021-02-17 00:00:00.0; 12(1), p. 1078.
EPub date: 2021-02-17 00:00:00.0.
PMID: 33597508
Related Citations

Breast cancer risk factors and survival by tumor subtype: pooled analyses from the Breast Cancer Association Consortium.
Authors: Morra A. , Jung A.Y. , Behrens S. , Keeman R. , Ahearn T.U. , Anton-Cluver H. , Arndt V. , Augustinsson A. , Auvinen P.K. , Beane Freeman L.E. , et al. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2021-01-26 00:00:00.0; , .
EPub date: 2021-01-26 00:00:00.0.
PMID: 33500318
Related Citations

A Population-Based Study of Genes Previously Implicated in Breast Cancer.
Authors: Hu C. , Hart S.N. , Gnanaolivu R. , Huang H. , Lee K.Y. , Na J. , Gao C. , Lilyquist J. , Yadav S. , Boddicker N.J. , et al. .
Source: The New England Journal Of Medicine, 2021-01-20 00:00:00.0; , .
EPub date: 2021-01-20 00:00:00.0.
PMID: 33471974
Related Citations

Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma.
Authors: Yadav S. , Kasi P.M. , Bamlet W.R. , Ho T.P. , Polley E.C. , Hu C. , Hart S.N. , Rabe K.G. , Boddicker N.J. , Gnanaolivu R.D. , et al. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2020-12-15 00:00:00.0; 26(24), p. 6505-6512.
EPub date: 2020-10-07 00:00:00.0.
PMID: 33028596
Related Citations

Transcriptome-wide association study of breast cancer risk by estrogen-receptor status.
Authors: Feng H. , Gusev A. , Pasaniuc B. , Wu L. , Long J. , Abu-Full Z. , Aittomäki K. , Andrulis I.L. , Anton-Culver H. , Antoniou A.C. , et al. .
Source: Genetic Epidemiology, 2020 07; 44(5), p. 442-468.
EPub date: 2020-03-01 00:00:00.0.
PMID: 32115800
Related Citations

Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.
Authors: Liu J. , Prager-van der Smissen W.J.C. , Collée J.M. , Bolla M.K. , Wang Q. , Michailidou K. , Dennis J. , Ahearn T.U. , Aittomäki K. , Ambrosone C.B. , et al. .
Source: Scientific Reports, 2020-06-16 00:00:00.0; 10(1), p. 9688.
EPub date: 2020-06-16 00:00:00.0.
PMID: 32546843
Related Citations

Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women.
Authors: Palmer J.R. , Polley E.C. , Hu C. , John E.M. , Haiman C. , Hart S.N. , Gaudet M. , Pal T. , Anton-Culver H. , Trentham-Dietz A. , et al. .
Source: Journal Of The National Cancer Institute, 2020-05-19 00:00:00.0; , .
EPub date: 2020-05-19 00:00:00.0.
PMID: 32427313
Related Citations

Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
Authors: Yadav S. , Hu C. , Hart S.N. , Boddicker N. , Polley E.C. , Na J. , Gnanaolivu R. , Lee K.Y. , Lindstrom T. , Armasu S. , et al. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2020-05-01 00:00:00.0; 38(13), p. 1409-1418.
EPub date: 2020-03-03 00:00:00.0.
PMID: 32125938
Related Citations

Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort.
Authors: Li H. , LaDuca H. , Pesaran T. , Chao E.C. , Dolinsky J.S. , Parsons M. , Spurdle A.B. , Polley E.C. , Shimelis H. , Hart S.N. , et al. .
Source: Genetics In Medicine : Official Journal Of The American College Of Medical Genetics, 2020 Apr; 22(4), p. 701-708.
EPub date: 2019-12-19 00:00:00.0.
PMID: 31853058
Related Citations

Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.
Authors: Patel V.L. , Busch E.L. , Friebel T.M. , Cronin A. , Leslie G. , McGuffog L. , Adlard J. , Agata S. , Agnarsson B.A. , Ahmed M. , et al. .
Source: Cancer Research, 2020-02-01 00:00:00.0; 80(3), p. 624-638.
EPub date: 2019-11-13 00:00:00.0.
PMID: 31723001
Related Citations

A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.
Authors: Escala-Garcia M. , Abraham J. , Andrulis I.L. , Anton-Culver H. , Arndt V. , Ashworth A. , Auer P.L. , Auvinen P. , Beckmann M.W. , Beesley J. , et al. .
Source: Nature Communications, 2020-01-16 00:00:00.0; 11(1), p. 312.
EPub date: 2020-01-16 00:00:00.0.
PMID: 31949161
Related Citations

Prediction of the functional impact of missense variants in BRCA1 and BRCA2 with BRCA-ML.
Authors: Hart S.N. , Polley E.C. , Shimelis H. , Yadav S. , Couch F.J. .
Source: Npj Breast Cancer, 2020; 6, p. 13.
EPub date: 2020-04-29 00:00:00.0.
PMID: 32377563
Related Citations

Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification.
Authors: Parsons M.T. , Tudini E. , Li H. , Hahnen E. , Wappenschmidt B. , Feliubadaló L. , Aalfs C.M. , Agata S. , Aittomäki K. , Alducci E. , et al. .
Source: Human Mutation, 2019 Sep; 40(9), p. 1557-1578.
PMID: 31131967
Related Citations

Two truncating variants in FANCC and breast cancer risk.
Authors: Dörk T. , Peterlongo P. , Mannermaa A. , Bolla M.K. , Wang Q. , Dennis J. , Ahearn T. , Andrulis I.L. , Anton-Culver H. , Arndt V. , et al. .
Source: Scientific Reports, 2019-08-29 00:00:00.0; 9(1), p. 12524.
EPub date: 2019-08-29 00:00:00.0.
PMID: 31467304
Related Citations

Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.
Authors: Qian F. , Rookus M.A. , Leslie G. , Risch H.A. , Greene M.H. , Aalfs C.M. , Adank M.A. , Adlard J. , Agnarsson B.A. , Ahmed M. , et al. .
Source: British Journal Of Cancer, 2019 07; 121(2), p. 180-192.
EPub date: 2019-06-19 00:00:00.0.
PMID: 31213659
Related Citations

BRCA1 and BRCA2 Pathogenic Sequence Variants in Women of African Origin or Ancestry.
Authors: Friebel T.M. , Andrulis I.L. , Balmaña J. , Blanco A.M. , Couch F.J. , Daly M.B. , Domchek S.M. , Easton D.F. , Foulkes W.D. , Ganz P.A. , et al. .
Source: Human Mutation, 2019-05-21 00:00:00.0; , .
EPub date: 2019-05-21 00:00:00.0.
PMID: 31112363
Related Citations

Genome-wide association study of germline variants and breast cancer-specific mortality.
Authors: Escala-Garcia M. , Guo Q. , Dörk T. , Canisius S. , Keeman R. , Dennis J. , Beesley J. , Lecarpentier J. , Bolla M.K. , Wang Q. , et al. .
Source: British Journal Of Cancer, 2019 Mar; 120(6), p. 647-657.
EPub date: 2019-02-21 00:00:00.0.
PMID: 30787463
Related Citations

Shared heritability and functional enrichment across six solid cancers.
Authors: Jiang X. , Finucane H.K. , Schumacher F.R. , Schmit S.L. , Tyrer J.P. , Han Y. , Michailidou K. , Lesseur C. , Kuchenbaecker K.B. , Dennis J. , et al. .
Source: Nature Communications, 2019-01-25 00:00:00.0; 10(1), p. 431.
EPub date: 2019-01-25 00:00:00.0.
PMID: 30683880
Related Citations

Cancer susceptibility gene mutations in type I and II endometrial cancer.
Authors: Long B. , Lilyquist J. , Weaver A. , Hu C. , Gnanaolivu R. , Lee K.Y. , Hart S.N. , Polley E.C. , Bakkum-Gamez J.N. , Couch F.J. , et al. .
Source: Gynecologic Oncology, 2019 01; 152(1), p. 20-25.
EPub date: 2018-10-26 00:00:00.0.
PMID: 30612635
Related Citations

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.
Authors: Figlioli G. , Bogliolo M. , Catucci I. , Caleca L. , Lasheras S.V. , Pujol R. , Kiiski J.I. , Muranen T.A. , Barnes D.R. , Dennis J. , et al. .
Source: Npj Breast Cancer, 2019; 5, p. 38.
EPub date: 2019-11-01 00:00:00.0.
PMID: 31700994
Related Citations

Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome.
Authors: Yadav S. , Hart S.N. , Hu C. , Hillman D. , Lee K.Y. , Gnanaolivu R. , Na J. , Polley E.C. , Couch F.J. , Kohli M. .
Source: Jco Precision Oncology, 2019; 3, .
EPub date: 2019-09-17 00:00:00.0.
PMID: 32923857
Related Citations

Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer.
Authors: Hu C. , Hart S.N. , Polley E.C. , Gnanaolivu R. , Shimelis H. , Lee K.Y. , Lilyquist J. , Na J. , Moore R. , Antwi S.O. , et al. .
Source: Jama, 2018-06-19 00:00:00.0; 319(23), p. 2401-2409.
PMID: 29922827
Related Citations

Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models.
Authors: Hart S.N. , Hoskin T. , Shimelis H. , Moore R.M. , Feng B. , Thomas A. , Lindor N.M. , Polley E.C. , Goldgar D.E. , Iversen E. , et al. .
Source: Genetics In Medicine : Official Journal Of The American College Of Medical Genetics, 2018-06-08 00:00:00.0; , .
EPub date: 2018-06-08 00:00:00.0.
PMID: 29884841
Related Citations

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
Authors: Fasching P.A. , Loibl S. , Hu C. , Hart S.N. , Shimelis H. , Moore R. , Schem C. , Tesch H. , Untch M. , Hilfrich J. , et al. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2018-05-23 00:00:00.0; , p. JCO2017772285.
EPub date: 2018-05-23 00:00:00.0.
PMID: 29791287
Related Citations

The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity.
Authors: Colombo M. , Lòpez-Perolio I. , Meeks H.D. , Caleca L. , Parsons M.T. , Li H. , De Vecchi G. , Tudini E. , Foglia C. , Mondini P. , et al. .
Source: Human Mutation, 2018 May; 39(5), p. 729-741.
EPub date: 2018-04-06 00:00:00.0.
PMID: 29460995
Related Citations